Editas gets Australian clearance to start Strive trial of EDIT-401, reports Q3 2026 results
Editas said it received ethics and regulatory clearance to begin its Phase 1/2 Strive study of EDIT-401 in Australia, with dosing expected by year-end and initial safety data due in early 2027.
SEC filing